eloralintide tirzepatide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Eli Lilly's Eloralintide Phase 2

As of mid-2024, the average monthly cost of tirzepatide without insurance in Phoenix, AZ typically ranges from $1,000 to $1,200 for standard doses

Maintaining consistent hydration from the outset of therapy prevents volume depletion

Escalating too quickly significantly increases the risk of nausea, vomiting, and other gastrointestinal side effects

In the landmark SURMOUNT-1 trial, participants on the highest dose lost an average of 22.5% of their body weight over 72 weeks, but that loss accumulated steadily over time rather than all at once

Human research is limited, and health agencies recommend stopping the medication before trying to conceive

This complaint raises serious questions about medication potency and quality control